Restoring KLF9 function or targeting its regulatory networks (e.g., EZH2 inhibition) may offer novel therapeutic avenues to disrupt HCC progression and metastasis, warranting further exploration of its clinical potential. The gene discussed is EZH2; the disease is hepatocellular carcinoma.